As with KRAS-altered tumors and owing to its high overall prevalence in non-Sq NSCLC, TP53 alterations were the most frequent in EGFR-mutant tumors across all ancestries (61–67%), followed by CDKN2A (26–31%) and CDKN2B alterations (24–33%) (Fig. 3a, b, Supplementary Data 10). Here, KRAS is linked to non-small cell lung carcinoma.